A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

• Status: Not yet recruiting
• Trial end date: 2024-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Diagnosis of plaque psoriasis (PsO) for ≥ 6 months

• Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)

• Deemed by Investigator to be eligible for phototherapy or systemic therapy

• Psoriatic plaques must cover ≥ 10% of body surface area at baseline

• Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

Exclusion Criteria:

• Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)

• Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment

• Any significant acute or chronic medical illness

Other protocol-defined inclusion/exclusion criteria apply